药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Metacycline
Aranidipine
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Aranidipine.
Metacycline
Dosulepin
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Dosulepin.
Metacycline
Pinaverium
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Pinaverium.
Metacycline
Olodaterol
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Olodaterol.
Metacycline
Flumequine
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Flumequine.
Metacycline
Chlorcyclizine
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Chlorcyclizine.
Metacycline
Bupranolol
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Bupranolol.
Metacycline
Geranylgeranyl diphosphate
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Geranylgeranyl diphosphate.
Metacycline
Farnesyl diphosphate
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Farnesyl diphosphate.
Metacycline
Triptorelin
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Triptorelin.
Metacycline
Histrelin
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Histrelin.
Metacycline
Buserelin
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Buserelin.
Metacycline
Degarelix
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Degarelix.
Metacycline
Mepyramine
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Mepyramine.
Metacycline
Pasireotide
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Pasireotide.
Metacycline
Cariporide
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Cariporide.
Metacycline
Amisulpride
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Amisulpride.
Metacycline
Vernakalant
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Vernakalant.
Metacycline
Tandutinib
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Tandutinib.
Metacycline
Methsuximide
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Methsuximide.